Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine for Sleep in Depression
NCT02442713Unknown
- Sponsor
- Guangdong Provincial Mental Health Institute
- Start
- Nov 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fluvoxamine in major depressive disorder (MDD), sponsored by Guangdong Provincial Mental Health Institute. Primary endpoint: Change of sleep during Fluvoxamine treatment at 56 days. Status: unknown.
02
Drugs
fluvoxamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02442713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442713.